Equity Overview:
Share Outstanding (6/27/17): 8.5M
NASDAQ: TPIV
Market Cap (6/27/17): ~$32.4M
Price (6/27/17): $3.82
Cash Balance (3/31/17): ~$5.9M
$100+ Billion Immunotherapy Cancer Drug Market
The global market for cancer drugs is projected to top $150 billion by 2020 (IMS Health). Much of the
Harnessing the
body’s healing
power to combat
cancer.
TapImmune is poised to capture
part of the large and rapidly
growing cancer immunotherapy
market with next-generation T-cell
vaccine technology and unique
focus on women’s immune health.
growth is being driven by consistent innovations in cancer immunotherapy, which is expected to continue
growing to $75.8 billion by 2022 across major markets (GBI Research, 2016). TapImmune is currently
advancing its robust mid-stage clinical pipeline focused on breast and ovarian cancer.
PolyStart™ - Out-licensing Opportunity
Proprietary vaccine technology that directs enhanced expression of multiple peptide antigens from a single
DNA vector, at levels 4-fold or greater compared to conventional expression systems. PolyStart is versatile
and dynamic with the ability to direct synergistic immune responses against cancer or viral infections.
TapImmune is seeking opportunities to monetize PolyStart through strategic out-licensing or collaboration.
Industry-leading Clinical Collaborators
The company is working in collaboration with industry and clinical leaders such as the Mayo Clinic, Memorial
Sloan Kettering Cancer Center, and AstraZeneca, including two Phase 2 studies that are fully funded by
~$17 million in non-dilutive grants from the U.S. Department of Defense.
FDA Fast-Track
The company’s lead vaccine candidate, TPIV 200, has been fast-tracked by the FDA with an Orphan Disease
Designation. This will allow more frequent interaction from the FDA and the possibility of accelerated
review.
Q2 2017 - TPIV 200
Q3 2017 - TPIV 200
Q3 2017 - TPIV 200
Q3 2017 - TPIV 200
Achieved 50% enrollment in Phase 2
Publish long-term survival and
Complete interim analysis: Phase 2
Mayo Clinic to initiate 280-patient
TNBC dosing study
immune response data from Phase 1
ovarian combo study + durvalumab
Phase 2 TNBC efficacy study
Q3 2017 - TPIV 200
Q4 2017 - TPIV 100/110
Q4 2017/2018 - TPIV 100/110
Year End 2017 - PolyStart™
Complete patient enrollment in
File amended IND; Initiate Phase
Mayo clinic to initiate Phase 1b/2
File additional patents covering key
Phase 2 TNBC dosing study
1b/2 HER2/neu+ breast cancer study
HER2/neu+ DCIS study
aspects of technology platform
TPIV 200: Folate Receptor-Alpha
Preclinical
Phase 1
Phase 2
Phase 3
Platinum Resistant: Enrolling
Ovarian
Cancer
Collaborators: Astrazeneca, Memorial Sloan Kettering Cancer Center
Collaborators: TapImmune
Platinum Sensitive: Enrolling
TripleNegative
Breast
Cancer
Dosing Study: Enrolling
Collaborators: TapImmune
Collaborators: Mayo Clinic, Department of Defense
Full Trial (N=280): 2017 Start
TPIV 100/110: HER2/neu
HER2/
neu+
Breast
Cancers
HER2/neu+ Breast: 2017 IND
Collaborators: TapImmune
Collaborators: Mayo Clinic, Department of Defense
HER2/neu+ DCIS: 2017 Start
Disclaimer: Except for historical information contained herein, the statements in this fact sheet are “forward looking” within the meaning of the Private Securities Litigation Act of 1995. This fact sheet includes estimates and projections and, as such, reflects
only management's current expectations. A fuller discussion of TapImmune’s risks and uncertainties are described in the Company’s filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview.